Andrada Mining acquisition elevates the miner to emerging mid-tier status. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,356.00
Bid: 12,390.00
Ask: 12,394.00
Change: 28.00 (0.23%)
Spread: 4.00 (0.032%)
Open: 12,364.00
High: 12,454.00
Low: 12,322.00
Prev. Close: 12,328.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

BROKER RATINGS SUMMARY: S&P CapIQ Cuts Next To Buy From Strong Buy

Tue, 05th Jan 2016 09:43

LONDON (Alliance News) - The following shares received analyst recommendations Tuesday morning:
----------
FTSE 100
----------
S&P CAPITAL IQ CUTS NEXT TO 'BUY' ('STRONG BUY') - TARGET 85 (91) PENCE
----------
CREDIT SUISSE RAISES BUNZL PRICE TARGET TO 1780 (1660) PENCE - 'NEUTRAL'
----------
CREDIT SUISSE RAISES TRAVIS PERKINS TO 'OUTPERFORM' ('NEUTRAL') - TARGET 2255 (1838) PENCE
----------
Deutsche Bank Upgrades Tesco To Buy From Hold Ups Price Target To 210p From 200p
----------
JPMORGAN RAISES HIKMA PRICE TARGET TO 2700 (2500) PENCE - OVERWEIGHT
----------
JPMORGAN RAISES GLAXOSMITHKLINE PRICE TARGET TO 1390 (1370) PENCE - 'NEUTRAL'
----------
JPMORGAN RAISES ASTRAZENECA PRICE TARGET TO 4500 (4400) PENCE - 'NEUTRAL'
----------
Cantor Fitzgerald Raises Royal Mail To Buy From Hold Ups Price Target To 530p From 500p
----------
BARCLAYS CUTS ABERDEEN AM TO UNDERWEIGHT (EQUAL WEIGHT) - TARGET 250 (350) PENCE
----------
SOCGEN CUTS MARKS & SPENCER PRICE TARGET TO 595 (652) PENCE - 'BUY'
----------
JPMORGAN RAISES SMITH & NEPHEW PRICE TARGET TO 1089 (1024) PENCE - 'NEUTRAL'
----------
FTSE 250
----------
MORGAN STANLEY CUTS SSP GROUP TO 'UNDERWEIGHT' ('EQUAL-WEIGHT')
----------
HSBC INITIATES JLT GROUP WITH 'BUY' - TARGET 1020 PENCE
----------
JPMORGAN CUTS ROTORK PRICE TARGET TO 170 (180) PENCE - 'NEUTRAL'
----------
JPMORGAN CUTS HALFORDS GROUP PRICE TARGET TO 380 (460) PENCE - 'NEUTRAL'
----------
JPMORGAN RAISES BODYCOTE PRICE TARGET TO 510 (500) PENCE - 'UNDERWEIGHT'
----------
JPMORGAN CUTS BTG TO 'NEUTRAL' ('OVERWEIGHT') - TARGET 780 (900) PENCE
----------
GOLDMAN CUTS MELROSE INDUSTRIES PRICE TARGET TO 360 (380) PENCE - 'BUY'
----------
BARCLAYS RAISES LANCASHIRE HOLDINGS PRICE TARGET TO 428 (419) PENCE - UNDERWEIGHT
----------
BARCLAYS RAISES HISCOX PRICE TARGET TO 684 (645) PENCE - 'UNDERWEIGHT'
----------
GOLDMAN CUTS WEIR GROUP PRICE TARGET TO 1500 (1550) PENCE - 'BUY'
----------
GOLDMAN CUTS SPECTRIS PRICE TARGET TO 2130 (2200) PENCE - 'BUY'
----------
Deutsche Upgrades Morrisons To Hold From Sell, Price Target 155p
----------
MAIN MARKET AND AIM
----------
JPMORGAN CUTS OXFORD INSTRUMENTS PRICE TARGET TO 870 (950) PENCE - 'OVERWEIGHT'
----------
GOLDMAN CUTS OXFORD INSTRUMENTS PRICE TARGET TO 685 (700) PENCE - 'NEUTRAL'
----------
JPMORGAN RAISES SPIRE HEALTHCARE PRICE TARGET TO 395 (310) PENCE - 'NEUTRAL'
----------
JPMORGAN RAISES CAMBIAN PRICE TARGET TO 278 (222) PENCE - 'OVERWEIGHT'
----------
JPMORGAN RAISES ABCAM PRICE TARGET TO 606 (558) PENCE - 'NEUTRAL'
----------
By Arvind Bhunjun; arvindbhunjun@alliancenews.com; @ArvindBhunjun

Copyright 2016 Alliance News Limited. All Rights Reserved.

More News
16 Oct 2023 08:34

TOP NEWS: AstraZeneca's cancer drug gets priority review from US FDA

(Alliance News) - AstraZeneca PLC on Monday said that its new drug application for Tagrisso has been granted priority review in the US, after trial results extended progression-free survival.

Read more
4 Oct 2023 12:14

IN BRIEF: AstraZeneca's Forxiga drug shows positive results in trial

AstraZeneca PLC - Cambridge-based pharmaceutical maker - Says Forxiga drug meets primary endpoints in T2NOW phase three trial and shows "clinically meaningful" improvements in the glycaemic control among type two diabetes patients between the ages of 10 and 17. Adds safety results in patient cohort were consistent with those in adults with type two diabetes.

Read more
3 Oct 2023 16:55

LONDON MARKET CLOSE: Stocks red as rate rise fears continue to grow

(Alliance News) - Stocks in London were lower at the close on Tuesday after unexpectedly strong US job openings data added to fears that interest rates in the world's largest economy will stay higher for longer.

Read more
3 Oct 2023 11:59

LONDON MARKET MIDDAY: HSBC and StanChart help FTSE 100 outperform

(Alliance News) - London's FTSE 100 grew in confidence as Tuesday morning progressed, going into the afternoon in the green and outperforming European peers.

Read more
3 Oct 2023 08:36

TOP NEWS: AstraZeneca settles Nexium and Prilosec litigation

(Alliance News) - AstraZeneca PLC on Tuesday said it has settled legal matters involving its Nexium acid reflux and Prilosec heartburn products, parting with USD425 million.

Read more
3 Oct 2023 07:41

LONDON BRIEFING: Greggs sales rise; boohoo cuts revenue outlook

(Alliance News) - London's FTSE 100 is set to fall further on Tuesday, after a sell-off at the start of the week, with hawkish words from a US central banker reinforcing the 'higher-for-longer' interest rates messaging.

Read more
3 Oct 2023 07:24

AstraZeneca agrees to settle most Nexium, Prilosec claims

(Sharecast News) - Global pharmaceutical company AstraZeneca has agreed to settle litigation on product liability related to two of its widely-used heartburn drugs, Nexium and Prilosec, it announced on Tuesday.

Read more
25 Sep 2023 09:13

LONDON BROKER RATINGS: Jefferies raises AstraZeneca to 'buy'

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning:

Read more
25 Sep 2023 07:43

LONDON BRIEFING: Stocks seen lower; Aviva buys AIG's UK protection arm

(Alliance News) - Stocks in London were set to open lower on Monday as investors eyed fresh concerns for the already fragile Chinese property sector.

Read more
22 Sep 2023 08:42

LONDON MARKET OPEN: Stocks slip after central bank rate calls

(Alliance News) - Stock prices in London opened lower on Friday, but managed to avoid the steep declines seen in New York, as investors mulled over an eventful week dominated by central bank decisions.

Read more
22 Sep 2023 08:13

TOP NEWS: AstraZeneca's datopotamab deruxtecan shows positive results

(Alliance News) - AstraZeneca PLC on Friday said phase three data showed that datopotamab deruxtecan delivered improvement in progression-free survival in breast cancer patients.

Read more
22 Sep 2023 07:27

AstraZeneca reports positive findings from breast cancer threatment trial

(Sharecast News) - New high-level results from AstraZeneca's TROPION-Breast01 phase three trial, released on Friday, carried encouraging news for patients with inoperable or metastatic hormone receptor (HR)-positive, HER2-low or negative breast cancer.

Read more
20 Sep 2023 08:44

TOP NEWS: AstraZeneca's rare disease business buys Pfizer portfolio

(Alliance News) - AstraZeneca PLC on Wednesday said rare disease business Alexion has signed a purchase and licence agreement for a rare disease programme portfolio from Pfizer Inc.

Read more
15 Sep 2023 15:27

AstraZeneca and Daiichi Sankyo's Enhertu recommended for approval

(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd's Enhertu has been recommended for approval in the EU on Friday.

Read more
14 Sep 2023 08:25

Smith & Nephew brings BT Chief Financial Officer Simon Lowth to board

(Alliance News) - Smith & Nephew PLC on Thursday announced that BT Group PLC's chief financial officer, Simon Lowth, will join the board as independent non-executive director on January 1.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.